Blueprint Medicines Corp【BPMC】
| Dec 31,
2015 | Dec 31,
2016 | Dec 31,
2017 | Dec 31,
2018 | Dec 31,
2019 | Dec 31,
2020 | Dec 31,
2021 | Dec 31,
2022 | Dec 31,
2023 | Dec 31,
2024 |
|---|
| Net loss | - | - | -148 | -237 | -348 | 314 | -644 | -558 | -507 | -67 |
|---|
| Depreciation and amortization | 1 | 2 | 2 | 4 | 5 | 7 | 6 | 12 | 12 | 16 |
|---|
| Non-cash lease expense | - | - | - | - | 5 | 6 | 6 | 8 | 9 | 10 |
|---|
| Stock-based compensation | 5 | 6 | 13 | 31 | 55 | 76 | 92 | 99 | 93 | 109 |
|---|
| Noncash Interest Expense | - | - | - | - | - | - | - | 16 | 14 | 1 |
|---|
| Non-cash customer consideration | - | - | - | - | - | - | - | 28 | - | - |
|---|
| Non-cash debt extinguishment gain | - | - | - | - | - | - | - | - | - | 174 |
|---|
| Net (accretion of discount) amortization of premium on investments | - | - | - | - | - | - | - | - | 17 | 22 |
|---|
| Other | - | - | - | -0 | - | 0 | 3 | 3 | 1 | -1 |
|---|
| Accounts receivable | - | - | - | - | 1 | 6 | 18 | -2 | 21 | 33 |
|---|
| Unbilled accounts receivable | - | - | - | - | 23 | -5 | -6 | 4 | -13 | -0 |
|---|
| Inventory | - | - | - | - | - | 7 | 13 | 9 | 4 | 4 |
|---|
| Prepaid expenses and other current assets | 1 | -1 | 7 | -6 | 3 | 13 | -5 | 17 | -3 | 3 |
|---|
| Other assets | 1 | 0 | 0 | 4 | -0 | -1 | 2 | 16 | 5 | 11 |
|---|
| Accounts payable | 1 | 0 | 2 | -0 | 1 | -1 | 4 | -6 | 2 | 2 |
|---|
| Accrued expenses | 2 | 6 | 15 | 25 | 37 | 16 | 6 | 9 | 1 | 8 |
|---|
| Other long-term liabilities | - | - | - | - | - | - | - | - | -7 | -12 |
|---|
| Deferred revenue | - | - | - | 5 | -0 | -5 | -5 | -5 | -13 | -0 |
|---|
| Operating lease liabilities | - | - | - | - | - | - | -8 | -8 | -11 | -12 |
|---|
| Net cash used in operating activities | - | - | -120 | -175 | -278 | 387 | -299 | -502 | -437 | -193 |
|---|
| Purchases of property and equipment | 5 | 2 | 16 | 13 | 14 | 3 | 3 | 9 | 16 | 5 |
|---|
| Purchases of investments | - | 264 | 361 | 801 | 738 | 969 | 655 | 490 | 766 | 966 |
|---|
| Maturities of investments | - | 48 | 304 | 653 | 736 | 538 | 691 | 349 | 1,056 | 924 |
|---|
| Other | - | - | - | - | - | - | - | 0 | - | - |
|---|
| Net cash provided by (used in) investing activities | - | - | -76 | -161 | -16 | -434 | -226 | -150 | 274 | -48 |
|---|
| Proceeds from at-the-market offerings, net of issuance costs | - | - | - | - | - | 503 | - | - | - | 49 |
|---|
| Net proceeds from stock option exercises and employee stock purchase plan | - | - | - | - | - | 35 | 51 | 8 | 21 | 78 |
|---|
| Net proceeds from term loan facility | - | - | - | - | - | - | - | 138 | 98 | 147 |
|---|
| Proceeds from (Repayments of) Other Long-Term Debt | - | - | - | - | - | - | - | 416 | - | - |
|---|
| Principal payments for financing arrangements | - | - | - | - | - | - | - | - | - | 1 |
|---|
| Net cash provided by financing activities | - | - | 544 | 4 | 341 | 618 | 51 | 562 | 119 | 273 |
|---|
| Net increase (decrease) in cash, cash equivalents, and restricted cash | - | - | - | - | - | - | - | - | -44 | 33 |
|---|
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | - | - | - | - | - | - | - | -0 | 0 | -1 |
|---|
| Cash paid for interest | 0 | 0 | 0 | 0 | 0 | - | - | 10 | 38 | 80 |
|---|
| Capital Expenditures Incurred but Not yet Paid | 1 | - | 4 | 1 | 1 | 0 | 0 | 0 | 1 | 0 |
|---|
| Income Taxes Paid, Net | - | - | - | - | 0 | 1 | 1 | 7 | -0 | 1 |
|---|